Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS2 | Q07890 | 1/20 | 0.36 |
| ▸ | NQO1 | P15559 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3628030 | 0.77 | SOS2 (0.38) | SOS2NQO1MAPK1L3MBTL1 | |
| SCHEMBL3915592 | 0.77 | EGLN2 (0.41) | SOS2NQO1CDC7EGLN2ADORA2A | |
| SCHEMBL10268214 | 0.74 | SOS2 (0.48) | SOS2NQO1MEN1KMT2AMAPK1 | |
| SCHEMBL1449669 | 0.74 | EGLN2 (0.43) | SOS2NQO1CDC7EGLN2ADORA2A | |
| SCHEMBL30955922 | 0.74 | SOS2 (0.36) | SOS2NQO1CDC7EGLN2 | |
| SCHEMBL23795443 | 0.74 | SOS2 (0.36) | SOS2NQO1CDC7EGLN2KMT2A | |
| SCHEMBL16914426 | 0.74 | HTT (0.42) | SOS2NQO1CDC7EGLN2ADORA2A | |
| SCHEMBL25268051 | 0.74 | KHK (0.36) | SOS2NQO1CDC7EGLN2ADORA2A | |
| SCHEMBL1311117 | 0.74 | SOS2 (0.36) | SOS2NQO1CDC7EGLN2 | |
| SCHEMBL2981097 | 0.74 | NQO1 (0.38) | SOS2NQO1EGLN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828360-B2 | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160297796-A1 | PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-20150368244-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| WO-2014078378-A1 | PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| EP-2324024-B1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH INC (US) | 2012-09-26 | — | — | EP | disclosed |
| CN-102119162-A | Diazacarbazoles and methods of use | GENENTECH INC | 2011-07-06 | — | — | CN | disclosed |
| US-20110124654-A1 | DIAZACARBAZOLES AND METHODS OF USE | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2011-05-26 | — | — | US | disclosed |
| EP-2324024-A1 | DIAZACARBAZOLES AND METHODS OF USE | Genentech, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| CN-101948425-A | As the compound of glucocorticoid ligands, the pharmaceutical composition that comprises them, test kit and preparation method thereof | BOEHRINGER INGELHEIM PHARMA | 2011-01-19 | — | — | CN | disclosed |
| CN-1976705-B | 1,1, 1-trifluoro-4-phenyl-4-methyl-2- (1H-pyrrolo [2,3-C ] pyridin-2-ylmethyl) pentan-2-ol derivatives and related compounds as glucocorticoid ligands for the treatment of inflammatory diseases and diabetes | BOEHRINGER INGELHEIM PHARMA | 2010-09-22 | — | — | CN | disclosed |
| WO-2009151589-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| CN-1976705-A | 1,1, 1-trifluoro-4-phenyl-4-methyl-2- (1H-pyrrolo [2, 3-C ] pyridin-2-ylmethyl) pentan-2-ol derivatives and related compounds as glucocorticoid ligands for the treatment of inflammatory diseases and diabetes | BOEHRINGER INGELHEIM PHARMA (US) | 2007-06-06 | — | — | CN | disclosed |
| EP-1673088-A1 | 1,1,1- TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO¬2,3-C|PYRIDIN-2-YLMETHYL)PENTAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS GLUCOCORTICOID LIGANDS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND DIABETES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20050176706-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005030213-A1 | 1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297796-A1 | PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | TK1, UACA, TYMP | SOS2 4655/4885NQO1 4045/4885CDC7 247/4885 |
| US-20050176706-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | NR3C1, NR3C2, MC2R | SOS2 4101/4885NQO1 3742/4885CDC7 2053/4885 |
| US-20110124654-A1 | DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | SOS2 1606/4885NQO1 1427/4885CDC7 15/4885 |
| US-20150368244-A1 | DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | SOS2 1606/4885NQO1 1427/4885CDC7 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.